Atmospheric Pressure Cold Plasma for Moderate-to-severe Tinea Pedis

Tinea pedis (athlete's foot) is a common and highly contagious fungal infection of the feet. Moderate-to-severe cases present with extensive skin lesions, severe symptoms, frequent recurrences, and increased risk of complications, often proving refractory to conventional topical therapies. Anatomical niches, poor drug penetration, and antifungal resistance make effective management challenging and negatively impact patients' quality of life. Current treatments, including topical and systemic antifungals or physical modalities, are often limited by incomplete efficacy, complexity, or poor adherence. Therefore, more effective and practical treatment options are urgently needed. Atmospheric pressure cold plasma (CAP) is an innovative technology that generates reactive species capable of targeting pathogens while preserving normal tissue. CAP has demonstrated strong antimicrobial effects and promotes wound healing in biomedical research. This study will evaluate the efficacy and safety of CAP in treating moderate-to-severe tinea pedis, aiming to address unmet clinical needs and support future clinical application.

NCT Number	NCT07056660
Lead Sponsor	Shenyang Medical College Collaborators: Tsinghua University
Conditions	Tinea Pedis
Enrollment	220 participants
Start Date	2025-07-25
Primary Completion	2026-07-15 (estimated)
Study Completion	2026-08-20 (estimated)
Updated on ClinicalTrials.gov	2026-01-02